Table 2.
Clinical features | Circ‐LARP4 low expression (n = 36)* | Circ‐LARP4 high expression (n = 36)* | P value |
---|---|---|---|
Age, No. (%) | |||
<18 y | 19 (52.8) | 19 (52.8) | 1.000 |
≥18 y | 17 (47.2) | 17 (47.2) | |
Gender, No. (%) | |||
Female | 16 (44.4) | 14 (38.9) | .633 |
Male | 20 (55.6) | 22 (61.1) | |
Tumor location, No. (%) | |||
Femur | 18 (50.0) | 20 (55.5) | .750 |
Tibia | 14 (38.9) | 11 (30.6) | |
Others | 4 (11.1) | 5 (13.9) | |
WHO classification of sarcoma, No. (%) | |||
Conventional: chondroblastic | 5 (13.9) | 5 (13.9) | .755 |
Conventional: osteoblastic | 25 (69.5) | 22 (61.1) | |
Conventional: other | 3 (8.3) | 6 (16.7) | |
Telangiectatic | 3 (8.3) | 3 (8.3) | |
Pathological fracture, No. (%) | |||
No | 27 (75.0) | 31 (86.1) | .234 |
Yes | 9 (25.0) | 5 (13.9) | |
Enneking stage, No. (%) | |||
IIA | 2 (5.6) | 9 (25.0) | .022 |
IIB | 34 (94.4) | 27 (75.0) | |
Surgery type, No. (%) | |||
Amputation | 11 (30.6) | 10 (27.8) | .759 |
Limb salvage | 25 (69.4) | 26 (72.2) |
Low expression and high expression were categorized by the median value of circ‐LARP4 relative expression in tumor. Comparison was determined by the chi‐square test. WHO: World Health Organization.